Door closes on drug discovery. IBM is tapering off sales of its Watson for Drug Discovery product in favor of other healthcare offerings using the AI technology, STAT reported this morning. The ...

IBM has discontinued the development and sales of its Watson for Drug Discovery product due to poor financial performance, according to STAT. This usage of IBM's Watson artificial intelligence ...

As the AI hype-cycle has built, we've been treated to a plethora of claims about what sorts of improvements and breakthroughs the technology can deliver. One of the most fundamental -- and potentially ...

Boehringer Ingelheim will harness an artificial intelligence model trained in the computer labs of IBM as the German drugmaker becomes the latest Big Pharma to apply machine learning tools to its drug ...

IBM is spending $1 billion to give Watson its own New York City-based business division as it seeks commercial applications for its Jeopardy-winning supercomputer in healthcare and other fields. But ...